This clinical trial is focused on studying a rare blood disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). This condition causes blood clots to form in small blood vessels, leading to a low platelet count, which can result in bleeding and other serious health issues. The study is testing a treatment called TAK-755 (rADAMTS13), which is a type of protein therapy designed to help manage this condition. The trial will also involve the use of other medications, including Rituximab, a monoclonal antibody, and Glucocorticoids, which are a type of steroid medication.

The purpose of the study is to assess the safety of TAK-755 in treating patients with iTTP. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will compare the effects of TAK-755 with minimal or no plasma exchange, a procedure that is often used to treat iTTP by removing and replacing the plasma in the blood. The trial will monitor participants over a period to observe any side effects and to see how well the treatment works in managing the disease.

Throughout the study, researchers will track various health indicators to understand the treatment’s impact on the disease. This includes monitoring the occurrence of any adverse events, the time it takes for patients to respond to the treatment, and any changes in specific blood markers. The study aims to provide valuable information on how TAK-755 can be used to treat iTTP effectively and safely, potentially offering a new option for managing this challenging condition.